Olorofim not checked

F2G Biotech GmbH · F901318

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
6 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Arm A: Oral olorofim loading dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 followed by a maintenance dose of 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 168 (± 7 days)”In the company’s words, NCT07712484 on ClinicalTrials.gov
Tested for
Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection, Coccidioides Immitis Infection, Coccidioides Posadasii Infection, Coccidioidomycosis Infection, San Joaquin Valley Fever, Valley Fever
Main trialPhase 2
“The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).”In the company’s words, NCT07712484 on ClinicalTrials.gov
Other names
F901318
Given with
Ambisome (Astellas)Other companies’ drugs in its trials

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Jun 2028 A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care
Phase 3Completed 18 Nov 2025 Olorofim Aspergillus Infection Study
Phase 2Completed 10 Feb 2023 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Phase 1Completed 15 Sep 2020 A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim
Phase 1Completed 24 Oct 2021 A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Phase 1Completed 13 Dec 2022 A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Olorofim

Following is part of Solo: you see every change to Olorofim the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in